Amy Robach


Good news for Amy Robach!

The Good Morning America news anchor completed her final round of chemotherapy Thursday. "Today marks my eighth and final round of chemotherapy," the TV journalist, 40, said in a taped segment that aired the following day. "This is my final treatment. The doctors say I graduate today."

"I decided to have most of my medical moments remain private, but this one I wanted to share," Robach said. "This is a huge milestone for me and for anyone else who has battled cancer, and I join the ranks of 2.8 million U.S. women who are breast cancer survivors." She also shared a photo collage on Twitter, writing, "I wanted to share this moment with you to encourage anyone facing this battle."

In November 2013, Robach announced that she'd been diagnosed with breast cancer after undergoing a live on-air mammogram the month prior. She also said she planned undergo a bilateral mastectomy.

Robach described her 20 weeks of chemotherapy treatment as an "uphill battle" and admitted that some days were "much harder than others...I was one of the lucky ones, only losing about one quarter of my hair," she revealed. "But no one escapes all of the side effects, both physical and emotional."

Now that her final round of chemotherapy is complete, she plans to help raise awareness about early detection for breast cancer and help other women fight the disease. "I plan on living each day to the fullest, thankful and grateful, and encouraging so many women who are out there, who are still in the thick of it, who have yet to fight this fight, that you can do it, you can get through this one step a time," said Robach, who has two daughters and three stepsons. "I am there for you. I am there with you."

  • Share
  • Tweet
  • Share

We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences. By using the site, you consent to these cookies. For more information on cookies including how to manage your consent visit our Cookie Policy.